{
  "id": 7690973,
  "title": "Deep reinforcement learning-driven discovery of a MsbA-targeted small-molecule antibiotic for the treatment of Acinetobacter baumannii infection",
  "url": "https://urgent.news/2026/09/15/deep-reinforcement-learning-driven-discovery-of-a-msba-targeted-small",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.12.751098v1?rss=1"
  },
  "original_language": "en",
  "account": "Deep reinforcement learning has been instrumental in the discovery of a new small-molecule antibiotic, Y-11, capable of targeting and combating Acinetobacter baumannii infections. MsbA, a crucial protein involved in lipopolysaccharide biosynthesis, was identified as a promising target for developing novel antibiotics. However, existing MsbA-targeted molecules often lacked efficacy or had undesirable properties, prompting the need for an expanded chemical space. The research team utilized two AI-based tools, Link-INVENT and AutoMolDesigner, to design and optimize molecules based on the template cerastecin Cpd4. Through molecular design, chemical derivatization, and antibacterial activity evaluation, they identified Y-11 as a potent candidate. Y-11 displayed similar potency to Cpd4 against carbapenem-resistant A. baumannii, while exhibiting reduced cytotoxicity, hemolysis, and spontaneous resistance frequency. In vivo efficacy studies confirmed that Y-11 effectively reduced bacterial loads in mice infected with A. baumannii. Mechanistic studies, comprising molecular dynamics simulations, biochemical assays, and transmission electron microscopy analysis, suggested that Y-11 functions by competitively binding to the substrate binding site of MsbA and modulating its ATPase activity, thereby inhibiting lipooligosaccharide transport and impairing outer membrane formation. The successful discovery of Y-11 via AI-driven drug design presents a promising foundation for future antibiotic development.",
  "summary": "Antibiotics with new mechanisms are highly pursued to address the threat of infections caused by drug-resistant Gram-negative bacteria. Targeting MsbA, a key protein of the lipopolysaccharide biosynthesis pathway, represents a promising strategy to discover new classes of antibiotics. However, currently available MsbA-targeted molecules either lack sufficient potency or have unfavorable…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}